Last checked at 23 Sep 2016 07:00
For immediate release | 23 September 2016 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Dealings
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, was notified on 22 September 2016 that, on the same day, John Dawson, Chief Executive Officer of the Company, sold 3,000,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 45.25 pence per share.
Following this transaction, Mr Dawson's total beneficial interest in the Company is 56,576,402 Ordinary Shares, representing approximately 12.0% of the Company's issued share capital.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Officer Andrew Franklin, Chief Financial Officer | |
Sarah Robinson, Company Secretary | |
www.alliancepharma.co.uk
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
ANNEX
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| John Dawson | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Executive Officer | ||||
b)
| Initial notification /Amendment
| Initial | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Alliance Pharma plc | ||||
b)
| LEI
| n/a | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| 1p ordinary shares
ISIN: GB0031030819
| ||||
b)
| Nature of the transaction
| Sale | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
| Total of 3,000,000 shares at 45.25p | ||||
e)
| Date of the transaction
| 22 September 2016 | ||||
f)
| Place of the transaction
| London Stock Exchange, AIM | ||||